BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551]
URL: https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm
Number Citing Articles
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi. Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dosePharmacology Research & Perspectives 2021; 9(4) doi: 10.1002/prp2.811
Huan-Keat Chan, Mohamed Azmi Hassali, Rosaida Md Said, Haniza Omar, Noor Aliza Abd Mutalib, Frederick Walter De Rozario, Muhammad Radzi Abu Hassan. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in MalaysiaHepatitis Monthly 2021; 21(3) doi: 10.5812/hepatmon.113226
Innocent Kamali, Dale A. Barnhart, Françoise Nyirahabihirwe, Jean de la Paix Gakuru, Mariam Uwase, Esdras Nizeyumuremyi, Stephen Walker, Christian Mazimpaka, Jean de Dieu Gatete, Jean Damascene Makuza, Janvier Serumondo, Fredrick Kateera, Jean d’Amour Ndahimana. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approachBMC Infectious Diseases 2021; 21(1) doi: 10.1186/s12879-021-05920-3
Heba Shawky, Reem El-Shenawy, Naiera M. Helmy. Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patientsHuman Antibodies 2021; : 1 doi: 10.3233/HAB-211504